As of Beijing time The data is from a third-party organization and is only for reference.
For actual information, please refer to：www.eastmoney.com
Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)
Tel: +1(626)986-9880
Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK
Tel: 0044 7790 816 954
Email: marketing@medicilon.com
Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)
Postcode: 201299
Tel: +86 (21) 5859-1500 (main line)
Fax: +86 (21) 5859-6369
© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888 | Website Map
Business Inquiry
Global：
Email:marketing@medicilon.com
+1(626)986-9880(U.S.)
0044 7790 816 954 (Europe)
China：
Email: marketing@medicilon.com.cn
Tel: +86 (21) 5859-1500
On December 9-10, 2019, the “Fifth Pharmaceutical Frontier Summit Forum” was held concurrently during the “Nanjing International Life and Health Technology Expo”, with the theme of “Leading Life Science and Technology, Empowering the Health Industry”, through academician reports and round tables Dialogues, special exchanges, exhibitions and other ways to gather innovative resources, focus on the frontiers of strategy, talk to top experts, share investment opportunities, integrate global resources, and promote the innovative development of my country’s biomedical industry.
Among them, the roundtable session invited Dr. Chunlin Chen, the founder & CEO of Medicilon, to participate in the discussion and discuss the “Golden Decade” of innovative drug research and development & international cooperation.
The discussion site of the round table forum of the 5th Pharmaceutical Frontier Summit
At the forum, Dr. Chunlin Chen shared the main service content of Medicilon Biologics in the past ten years: first, to leverage on the good development of China’s innovative drug research and development to vigorously develop domestic business; second, to adhere to the policy of dual reporting of innovative drugs during registration and application. Helped many domestic enterprises to obtain foreign clinical trial approvals. Dr. Chen hopes that companies can strengthen international cooperation, insist on opening to the outside world, gain international recognition, and pay attention to both scientific and international development.
Shanghai Medicilon is committed to the research and development of innovative drugs. Since 2015, the company has participated in the completion of more than 60 new drug and generic drug projects that have been approved by China CFDA/NMPA, US FDA, and Australian TGA to enter Phase I clinical trials. . In the future, Medicilon looks forward to helping more innovative drug R&D projects and contributing more strength to the early entry of new drugs into the clinical stage!
contact us
Email: marketing@medicilon.com
Tel: +86 (21) 5859-1500
Related Articles:
API process development of the new drug IND stage
Medicilon’s IND Application Platform
Medicilon successfully held CFDA IND seminar in Seoul, South Korea
Medicilon sponsored the seminar on new drug preclinical research and IND application strategy
marketing@medicilon.com
ABOUT
